CellCarta and Lunit entered a partnership to integrate AI pathology solutions into clinical trial workflows and biomarker development. The collaboration pairs CellCarta’s global clinical pathology execution capacity with Lunit’s “Scope” platform for image analysis and biomarker testing. The firms said they are assessing pilot opportunities in trial operations and AI image analysis, with plans to expand use cases as validation is completed. A stated focus is interoperability—helping sponsors generate high-quality evidence efficiently while reducing operational friction during clinical development. CellCarta CEO Dusty Tenney linked the deal to customer demand for AI-enabled pathology services. Lunit’s CEO Brandon Beomseok Suh emphasized that scalable adoption requires operational readiness and that working together helps bridge today’s trial workflows to future commercialization models. For clinical and biotech operators, the practical takeaway is that AI pathology is moving from isolated pilots toward integrated trial infrastructure, where CDx/bioanalysis, QC, and evidence generation are treated as first-order deliverables.